Classical Hodgkin lymphoma (cHL) is a lymphoid malignancy of germinal centre (GC) B-cell origin1, which is characterised by Hodgkin and Reed–Sternberg (HRS) cells with a dominant background population of reactive inflammatory cells1. Of the four major subtypes of cHL, nodular sclerosis Hodgkin ...
The burden of late effects among Hodgkin lymphoma (HL) survivors treated according to contemporary protocols remains poorly characterized. We used nation‐wide registers to assess number of inpatient bed‐days and specialist outpatient visits among 1048 HL‐patients (<25 years, diagnosed 1990‐2010)...
【疾病名】非霍奇金淋巴瘤 【英文名】non-Hodgkinlymphoma 【别名】非何杰金淋巴瘤;非霍奇金恶性淋巴肿瘤 【ICD号】C85.9 【病因和发病机制研究的进展】 1.病因研究进展 2.发病机制研究进展 【诊断研究进展】 1.辅助诊断检查进展 (1)实验室检查进展: 1.非霍奇金淋巴瘤细胞DNA含量的测定及临床意义卫燕等(北京大...
Other possible limitation is the use of ICD9, that classification has not different code for each type of lymphoma included in the LNH; as a result we can not know the spatial patterns of each individual type. Moreover, mortality data only includes the more aggressive type of lymphoma. Less...
As a result, it is not yet possible to provide long-term comparisons of incidence and survival trends for specific types of non-Hodgkin lymphoma with population-based data. This is also true of mortality data, which were only coded to ICD-10 from 2000 or later, and which are derived from...
The purpose of this study was to investigate associations between pesticide exposures and risk of Hodgkin lymphoma (HL) using data from the North American
We used the international classification of diseases 10 (ICD-10) codes C82–C85 to identify NHL cases and further specified cases as diffuse large B cell Results We identified 20,829 non-Hodgkin lymphoma cases and selected 41,658 controls. We removed 3243 ineligible controls (due to non-...
In Non-Hodgkin Lymphoma (NHL), the prevalence of OBI reactivation remains to be established. Methods In order to determine the prevalence of occult HBV reactivation in a large cohort of patients during chemotherapy for NHL, we analysed 498 NHL patients in a centre of Southern Italy. We ...
(1), 159 – 166 Second primary cancers after non-Hodgkin's lymphoma P Brennan et al 162 Table 2 Standardised incidence ratios of second primary cancers following NHL by follow-up period Less than 1 year 1 – 4 years 5 – 9 years At least 10 years Overall Cancer sites (ICD 9th ...
e19513#Background:Immune checkpoint inhibitors (ICIs) have recently been found to be effective in Hodgkin lymphoma (HL). However, given the impaired systemic immune response in HL, it is unclear whether immune-related adverse events (irAEs) would manifest differently in this population; data on ...